BridgeBio Pharma Reports First Patient Dosing in P-I/II Trial for BBP-398 + Lumakras (sotorasib) to Treat Non-Small Cell Lung Cancer
- The 1st patient has been dosed in the P-I/II trial evaluating the safety, tolerability, PK, PD & preliminary efficacy of BBP-398 + Lumakras in patients with KRAS G12C-mutated LA or metastatic NSCLC (dose expansion period) & advanced solid tumors with the KRAS G12C mutation (dose escalation period)
- The initial P-I study results are expected in 2023. The combination therapy received the FTD from the US FDA for KRAS G12C-mutated, metastatic NSCLC
- The preclinical studies showed synergistic efficacy for the combination therapies in a KRAS G12C-mutated NSCLC cell line-derived xenograft model. In May 2022, BridgeBio & BMS collaborated to develop & commercialize BBP-398 in oncology globally (Ex- mainland China & other Asian markets)
Ref: Businesswire | Image: BridgeBio
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
